Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case o...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Tomomi, Sunaga, Noriaki, Kasahara, Norimitsu, Takehara, Kazutaka, Yatomi, Masakiyo, Hara, Kenichiro, Koga, Yasuhiko, Maeno, Toshitaka, Hisada, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396375/
https://www.ncbi.nlm.nih.gov/pubmed/32529804
http://dx.doi.org/10.1111/1759-7714.13532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396375/
https://www.ncbi.nlm.nih.gov/pubmed/32529804
http://dx.doi.org/10.1111/1759-7714.13532

Ejemplares similares